Independent Financial Group LLC Buys Shares of 935 Medpace Holdings, Inc. $MEDP

Independent Financial Group LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 935 shares of the company’s stock, valued at approximately $449,000.

A number of other hedge funds have also recently made changes to their positions in MEDP. BOKF NA increased its position in Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. boosted its holdings in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. boosted its holdings in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC grew its stake in shares of Medpace by 3.4% in the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after acquiring an additional 26 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Medpace Trading Up 14.7%

Shares of NASDAQ MEDP opened at $605.82 on Friday. The firm has a 50 day moving average of $488.37 and a 200 day moving average of $493.74. The firm has a market capitalization of $17.30 billion, a price-to-earnings ratio of 35.51, a price-to-earnings-growth ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 109.14%. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the firm earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MEDP shares. BMO Capital Markets reduced their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Royal Bank Of Canada cut their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $502.00.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported second-quarter EPS of $4.25 and revenue of $707.3 million, both above expectations, showing that demand and execution remain strong. Medpace earnings report and conference call
• Positive Sentiment: The company raised fiscal 2026 guidance, signaling management has more confidence in its business momentum and future profitability. Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
• Positive Sentiment: Investors are also focusing on improving operating metrics, including a rebound in book-to-bill and a stronger backlog conversion rate, which suggest healthier future revenue visibility. Medpace: ‘Buy’ On Financial Metric Improvements And Solid Q2 2026 Earnings

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.